Global Digital Dose Inhalers Market to Reach $4.9 Billion by 2026

SAN FRANCISCO, March 16, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Digital Dose Inhalers - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace.

FACTS AT A GLANCE
What's New for 2022?

• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to our digital archives and MarketGlass Research Platform
• Complimentary updates for one year

Edition: 5; Released: February 2022
Executive Engagements: 576
Companies: 23 - Players covered include 3M Company; AptarGroup, Inc.; AstraZeneca Plc; Cipla Inc.; GlaxoSmithKline plc.; Glenmark Pharmaceuticals; H&T Presspart Manufacturing Ltd.; Koninklijke Philips N.V.; Novartis International AG; Opko Health, Inc.; Philips Respironics; Propeller Health; Sensirion AG Switzerland; Teva Pharmaceutical Industries Ltd. and Others.
Coverage: All major geographies and key segments
Segments: Product (Metered Dose, Dry Powder); Type (Branded, Generic); Application (Asthma, COPD, Other Applications)
Geographies: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry

ABSTRACT-

Global Digital Dose Inhalers Market to Reach $4.9 Billion by 2026
Digital dose inhalers are advanced, smart devices intended to treat and manage drug delivery for various respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD). Digital dose inhalers deliver accurate amount of drug to patient's lungs as a short burst of aerosolized medication. Patients can self-administer these medications through inhalation. These devices come with inbuilt sensors for recording inhaler use and measuring inspiratory flow in line with dose management. Growth in the global market is poised to benefit from rising prevalence of various respiratory disorders, favorable reimbursement policies and technological advances. The market for digital dose inhalers is propelled by rising incident of chronic respiratory conditions including asthma, respiratory allergies, chronic pulmonary obstructive disease (COPD) and obstructive sleep apnea that adversely affect quality of life of patients. COPD accounts for around 6% or more than 3 million deaths globally, with low- to middle-income nations reporting over 90% of these deaths, creating significant demand for advanced respiratory devices. The market is further driven by increasing aging population that is highly vulnerable to mild to severe forms of respiratory disorders. These next-generation devices are also benefitting from rising uptake of digital devices, pressing requirement for patient compliance to medications, need for dose tracking and high investment in R&D activity to come up with miniaturized, innovative devices.

Amid the COVID-19 crisis, the global market for Digital Dose Inhalers estimated at US$3.1 Billion in the year 2022, is projected to reach a revised size of US$4.9 Billion by 2026, growing at a CAGR of 13.1% over the analysis period. Metered Dose, one of the segments analyzed in the report, is projected to grow at a 12.4% CAGR to reach US$3.4 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Dry Powder segment is readjusted to a revised 14.3% CAGR for the next 7-year period. This segment currently accounts for a 35.7% share of the global Digital Dose Inhalers market. The Metered Dose segment dominates the market due to extensive availability, rising incident of chronic heart conditions and increasing healthcare spending. These inhalers present a user-friendly and cost-efficient option to users that ensures accurate delivery of the dose for inhalation. Metered dose inhalers are gaining from rising cases of respiratory conditions including chronic respiratory disorders, chronic obstructive pulmonary diseases and asthma. The segment is benefitting from increasing awareness regarding numerous advantages of advanced devices over conventional options. The metered dose inhaler segment is poised to be bolstered by increasing use of soft mist inhalers as a result of rising uptake of enhanced drug delivery systems coupled with ongoing technological advancements. On the other hand, the dry powder inhaler segment is predicted to experience the fastest growth rate over the coming years on account of increasing concerns associated with drug irritation caused by propellant components found in metered dose inhalers, like chlorofluorocarbons.

The U.S. Market is Estimated at $1.3 Billion in 2022, While China is Forecast to Reach $418.2 Million by 2026
The Digital Dose Inhalers market in the U.S. is estimated at US$1.3 Million in the year 2022. The country currently accounts for a 42.48% share in the global market. China, the world's second largest economy, is forecast to reach an estimated market size of US$418.2 Million in the year 2026 trailing a CAGR of 16.4% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11% and 11.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.6% CAGR while Rest of European market (as defined in the study) will reach US$480.1 Million by the end of the analysis period.

An interesting trend to note is the ongoing trials targeting the use of inhalers to treat COVID-19. Researchers have come up with an inhaler-based, life-saving treatment with the potential to protect COVID-19 patients from experiencing severe signs. The approach relies on a protein, interferon beta-1a (SNG001), which is produced by the body during viral infection. Inhalation of the protein is anticipated to trigger the immune response and prompt cells to fight against the virus. In another development, a group of researchers isolated an antibody from llamas with potential to treat or prevent COVID-19. The antibody would be delivered to patients using inhalers. More

MarketGlass™ Platform
Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide.

Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on iOS or Android

About Global Industry Analysts, Inc. & StrategyR™
Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years.

CONTACTS:
Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
www.StrategyR.com 
Email: [email protected] 

LINKS
Join Our Expert Panel 
https://www.strategyr.com/Panelist.asp 

Connect With Us on LinkedIn 
https://www.linkedin.com/company/global-industry-analysts-inc./ 

Follow Us on Twitter 
https://twitter.com/marketbytes 

Journalists & Media 
[email protected]

SOURCE Global Industry Analysts, Inc.